Hysbysiad contract
Adran I:
Endid
contractio
I.1) Enw a chyfeiriad
NHS England
7&8 Wellington Place
Leeds
LS1 4AP
UK
Person cyswllt: Stacey Thrower
E-bost: stacey.thrower@nhs.net
NUTS: UKE
Cyfeiriad(au) rhyngrwyd
Prif gyfeiriad: https://www.england.nhs.uk//
Cyfeiriad proffil y prynwr: https://www.england.nhs.uk//
I.3) Cyfathrebu
Mae'r dogfennau caffael ar gael ar gyfer mynediad uniongyrchol anghyfyngedig a llawn, yn rhad ac am ddim ar:
https://health-family.force.com/s/Welcome
Gellir cael gwybodaeth ychwanegol o'r cyfeiriad uchod
Rhaid anfon tendrau neu geisiadau i gymryd rhan yn electronig at:
https://health-family.force.com/s/Welcome
Rhaid anfon tendrau neu geisiadau i gymryd rhan i'r cyfeiriad uchod:
Mae cyfathrebu electronig yn gofyn am ddefnyddio offer a dyfeisiau nad ydynt ar gael yn gyffredinol. Mae mynediad uniongyrchol anghyfgyfyngiedig a llawn i'r offer a dyfeisiau hyn yn bosibl, yn rhad ac am ddim, yn:
https://health-family.force.com/s/Welcome
I.4) Y math o awdurdod contractio
Corff a lywodraethir gan gyfraith gyhoeddus
I.5) Prif weithgaredd
Iechyd
Adran II: Gwrthrych
II.1) Cwmpas y caffaeliad
II.1.1) Teitl
Provision of Community Pharmacy RSV and Pertussis Vaccination Enhanced Service
Cyfeirnod: AG24034
II.1.2) Prif god CPV
85100000
II.1.3) Y math o gontract
Gwasanaethau
II.1.4) Disgrifiad byr
NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU) on behalf of NHS England (NHSE) (The Commissioner) would like to notify the market of an opportunity to provide Community Pharmacy RSV and Pertussis Vaccination Enhanced Service within the Midlands Region.<br/><br/>Respiratory Syncytial Virus (RSV) is a virus that for most people causes a mild respiratory illness, but can be more serious for those, including older adults and infants, who are at risk of more severe respiratory disease. Following the Joint Committee on Vaccination and Immunisation (JCVI) recommendation, the Commissioner will commission from September 2024:<br/><br/>• an adult programme (predominately to be commissioned through general practice); and<br/>• an infant programme provided as vaccination during pregnancy (predominantly to be commissioned through NHS Trusts).<br/><br/>In addition, where there are areas of identified additional need, the Commissioner will commission community pharmacy to provide additional capacity and increased access to supplement the core provision of these two programmes. <br/><br/>Pertussis (whooping cough) is a respiratory disease that is caused by the Bordetella pertussis bacterium. Pertussis can cause serious and life-threatening complications including pneumonia, difficulty in breathing (apnoea) and seizures. Pertussis most commonly affects infants, and very young infants are at highest risk of serious complications, of needing admission to hospital or of dying.<br/><br/>Pregnant women are eligible for the Pertussis vaccine from 16 weeks pregnancy, although the optimal window for protection is between 20 and 32 weeks of pregnancy. Commissioners have commissioned general practice and NHS trusts to deliver the Pertussis vaccination programme for pregnant women.<br/><br/>In addition, where there are areas of identified additional need, the Commissioner will commission community pharmacy to provide the Pertussis vaccination programme opportunistically to pregnant women to supplement the core service provision.<br/><br/>This Procurement Process is for the service provision in the Midlands Region where up to 66 sites from multiple potential Suppliers will be selected to provide the Services from May 2025. The 66 successful sites will be in three ICBs within the Midlands Region, with 22 sites allocated per lot to allow the Commissioner to ensure an even geographical spread. Should fewer than 22 sites be awarded to a Lot, up to 4 additional sites may be awarded under alternative Lot(s) at the Commissioners discretion. The ICB's included in this procurement are NHS Black Country ICB, NHS Leicester, Leicestershire, & Rutland ICB & NHS Birmingham and Solihull ICB.<br/><br/>The value of the service provision resulting from this Procurement Process will be an Item of Service (IoS) fee of £9.58 for the administration of each RSV and pertussis vaccine to each eligible patient.<br/><br/>The number of eligible patients, and therefore the likely activity level, could change as a result of factors beyond the Commissioner’s control such as an increase or decrease in population of the local area, closure or merger of other nearby NHS health organisations, or patient.<br/><br/>Services will commence in May 2025 and will continue until 31st March 2027, with an option for the Commissioner to extend for 24 months until 31 March 2029.<br/><br/>Please note the deadline for responses to the ITT is 12:00PM (Mid-Day) on Friday 14th March 2025.
II.1.6) Gwybodaeth am lotiau
Mae’r contract hwn wedi’i rannu’n lotiau:
Ydy
Gellir cyflwyno tendrau ar gyfer pob lot
II.2) Disgrifiad
Rhif y Lot 1
II.2.1) Teitl
Lot 1: NHS Black Country ICB
II.2.2) Cod(au) CPV ychwanegol
85100000
II.2.3) Man cyflawni
Cod NUTS:
UKG
II.2.4) Disgrifiad o’r caffaeliad
NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU) on behalf of NHS England (NHSE) (The Commissioner) would like to notify the market of an opportunity to provide Community Pharmacy RSV and Pertussis Vaccination Enhanced Service within the Midlands Region.<br/><br/>Respiratory Syncytial Virus (RSV) is a virus that for most people causes a mild respiratory illness, but can be more serious for those, including older adults and infants, who are at risk of more severe respiratory disease. Following the Joint Committee on Vaccination and Immunisation (JCVI) recommendation, the Commissioner will commission from September 2024:<br/><br/>• an adult programme (predominately to be commissioned through general practice); and<br/>• an infant programme provided as vaccination during pregnancy (predominantly to be commissioned through NHS Trusts).<br/><br/>In addition, where there are areas of identified additional need, the Commissioner will commission community pharmacy to provide additional capacity and increased access to supplement the core provision of these two programmes. <br/><br/>Pertussis (whooping cough) is a respiratory disease that is caused by the Bordetella pertussis bacterium. Pertussis can cause serious and life-threatening complications including pneumonia, difficulty in breathing (apnoea) and seizures. Pertussis most commonly affects infants, and very young infants are at highest risk of serious complications, of needing admission to hospital or of dying.<br/><br/>Pregnant women are eligible for the Pertussis vaccine from 16 weeks pregnancy, although the optimal window for protection is between 20 and 32 weeks of pregnancy. Commissioners have commissioned general practice and NHS trusts to deliver the Pertussis vaccination programme for pregnant women.<br/><br/>In addition, where there are areas of identified additional need, the Commissioner will commission community pharmacy to provide the Pertussis vaccination programme opportunistically to pregnant women to supplement the core service provision.<br/><br/>This Procurement Process is for the service provision in the Midlands Region where up to 66 sites from multiple potential Suppliers will be selected to provide the Services from May 2025. The 66 successful sites will be in three ICBs within the Midlands Region, with 22 sites allocated per lot to allow the Commissioner to ensure an even geographical spread. Should fewer than 22 sites be awarded to a Lot, up to 4 additional sites may be awarded under alternative Lot(s) at the Commissioners discretion. The ICB's included in this procurement are NHS Black Country ICB, NHS Leicester, Leicestershire, & Rutland ICB & NHS Birmingham and Solihull ICB.<br/><br/>The value of the service provision resulting from this Procurement Process will be an Item of Service (IoS) fee of £9.58 for the administration of each RSV and pertussis vaccine to each eligible patient.<br/><br/>The number of eligible patients, and therefore the likely activity level, could change as a result of factors beyond the Commissioner’s control such as an increase or decrease in population of the local area, closure or merger of other nearby NHS health organisations, or patient.<br/><br/>Services will commence in May 2025 and will continue until 31st March 2027, with an option for the Commissioner to extend for 24 months until 31 March 2029.<br/><br/>The award criteria is as stated below:<br/><br/>Integration, collaboration and service sustainability - 20.00%<br/>Improving access, reducing health inequalities and facilitating choice - 45.00%<br/>Quality and Innovation - 25.00%<br/>Social Value - 10.00%<br/>Value - Pass / Fail<br/><br/>Please note the deadline for responses to the ITT is 12:00PM (Mid-Day) on Friday 14th March 2025.
II.2.5) Meini prawf dyfarnu
Nid pris yw’r unig faen prawf dyfarnu a dim ond yn y dogfennau caffael y mae’r holl feini prawf wedi’u nodi
II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig
Dechrau:
01/05/2025
Diwedd:
31/03/2029
Gall y contract hwn gael ei adnewyddu: Na
II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd
II.2.10) Gwybodaeth am amrywiadau
Derbynnir amrywiadau:
Na
II.2.11) Gwybodaeth am opsiynau
Opsiynau:
Ydy
Disgrifiad o’r opsiynau:
Services will commence in May 2025 and will continue until 31st March 2027, with an option for the Commissioner to extend for 24 months until 31 March 2029.
II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd
Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd:
Na
Rhif y Lot 2
II.2.1) Teitl
Lot 2: NHS Leicester, Leicestershire, & Rutland ICB
II.2.2) Cod(au) CPV ychwanegol
85100000
II.2.3) Man cyflawni
Cod NUTS:
UKF2
II.2.4) Disgrifiad o’r caffaeliad
NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU) on behalf of NHS England (NHSE) (The Commissioner) would like to notify the market of an opportunity to provide Community Pharmacy RSV and Pertussis Vaccination Enhanced Service within the Midlands Region.<br/><br/>Respiratory Syncytial Virus (RSV) is a virus that for most people causes a mild respiratory illness, but can be more serious for those, including older adults and infants, who are at risk of more severe respiratory disease. Following the Joint Committee on Vaccination and Immunisation (JCVI) recommendation, the Commissioner will commission from September 2024:<br/><br/>• an adult programme (predominately to be commissioned through general practice); and<br/>• an infant programme provided as vaccination during pregnancy (predominantly to be commissioned through NHS Trusts).<br/><br/>In addition, where there are areas of identified additional need, the Commissioner will commission community pharmacy to provide additional capacity and increased access to supplement the core provision of these two programmes. <br/><br/>Pertussis (whooping cough) is a respiratory disease that is caused by the Bordetella pertussis bacterium. Pertussis can cause serious and life-threatening complications including pneumonia, difficulty in breathing (apnoea) and seizures. Pertussis most commonly affects infants, and very young infants are at highest risk of serious complications, of needing admission to hospital or of dying.<br/><br/>Pregnant women are eligible for the Pertussis vaccine from 16 weeks pregnancy, although the optimal window for protection is between 20 and 32 weeks of pregnancy. Commissioners have commissioned general practice and NHS trusts to deliver the Pertussis vaccination programme for pregnant women.<br/><br/>In addition, where there are areas of identified additional need, the Commissioner will commission community pharmacy to provide the Pertussis vaccination programme opportunistically to pregnant women to supplement the core service provision.<br/><br/>This Procurement Process is for the service provision in the Midlands Region where up to 66 sites from multiple potential Suppliers will be selected to provide the Services from May 2025. The 66 successful sites will be in three ICBs within the Midlands Region, with 22 sites allocated per lot to allow the Commissioner to ensure an even geographical spread. Should fewer than 22 sites be awarded to a Lot, up to 4 additional sites may be awarded under alternative Lot(s) at the Commissioners discretion. The ICB's included in this procurement are NHS Black Country ICB, NHS Leicester, Leicestershire, & Rutland ICB & NHS Birmingham and Solihull ICB.<br/><br/>The value of the service provision resulting from this Procurement Process will be an Item of Service (IoS) fee of £9.58 for the administration of each RSV and pertussis vaccine to each eligible patient.<br/><br/>The number of eligible patients, and therefore the likely activity level, could change as a result of factors beyond the Commissioner’s control such as an increase or decrease in population of the local area, closure or merger of other nearby NHS health organisations, or patient.<br/><br/>Services will commence in May 2025 and will continue until 31st March 2027, with an option for the Commissioner to extend for 24 months until 31 March 2029.<br/><br/>The award criteria is as stated below:<br/><br/>Integration, collaboration and service sustainability - 20.00%<br/>Improving access, reducing health inequalities and facilitating choice - 45.00%<br/>Quality and Innovation - 25.00%<br/>Social Value - 10.00%<br/>Value - Pass / Fail<br/><br/>Please note the deadline for responses to the ITT is 12:00PM (Mid-Day) on Friday 14th March 2025.
II.2.5) Meini prawf dyfarnu
Nid pris yw’r unig faen prawf dyfarnu a dim ond yn y dogfennau caffael y mae’r holl feini prawf wedi’u nodi
II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig
Dechrau:
01/05/2025
Diwedd:
31/03/2029
Gall y contract hwn gael ei adnewyddu: Na
II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd
II.2.10) Gwybodaeth am amrywiadau
Derbynnir amrywiadau:
Na
II.2.11) Gwybodaeth am opsiynau
Opsiynau:
Ydy
Disgrifiad o’r opsiynau:
Services will commence in May 2025 and will continue until 31st March 2027, with an option for the Commissioner to extend for 24 months until 31 March 2029.
II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd
Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd:
Na
Rhif y Lot 3
II.2.1) Teitl
Lot 3: NHS Birmingham and Solihull ICB
II.2.2) Cod(au) CPV ychwanegol
85100000
II.2.3) Man cyflawni
Cod NUTS:
UKG3
II.2.4) Disgrifiad o’r caffaeliad
NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU) on behalf of NHS England (NHSE) (The Commissioner) would like to notify the market of an opportunity to provide Community Pharmacy RSV and Pertussis Vaccination Enhanced Service within the Midlands Region.<br/><br/>Respiratory Syncytial Virus (RSV) is a virus that for most people causes a mild respiratory illness, but can be more serious for those, including older adults and infants, who are at risk of more severe respiratory disease. Following the Joint Committee on Vaccination and Immunisation (JCVI) recommendation, the Commissioner will commission from September 2024:<br/><br/>• an adult programme (predominately to be commissioned through general practice); and<br/>• an infant programme provided as vaccination during pregnancy (predominantly to be commissioned through NHS Trusts).<br/><br/>In addition, where there are areas of identified additional need, the Commissioner will commission community pharmacy to provide additional capacity and increased access to supplement the core provision of these two programmes. <br/><br/>Pertussis (whooping cough) is a respiratory disease that is caused by the Bordetella pertussis bacterium. Pertussis can cause serious and life-threatening complications including pneumonia, difficulty in breathing (apnoea) and seizures. Pertussis most commonly affects infants, and very young infants are at highest risk of serious complications, of needing admission to hospital or of dying.<br/><br/>Pregnant women are eligible for the Pertussis vaccine from 16 weeks pregnancy, although the optimal window for protection is between 20 and 32 weeks of pregnancy. Commissioners have commissioned general practice and NHS trusts to deliver the Pertussis vaccination programme for pregnant women.<br/><br/>In addition, where there are areas of identified additional need, the Commissioner will commission community pharmacy to provide the Pertussis vaccination programme opportunistically to pregnant women to supplement the core service provision.<br/><br/>This Procurement Process is for the service provision in the Midlands Region where up to 66 sites from multiple potential Suppliers will be selected to provide the Services from May 2025. The 66 successful sites will be in three ICBs within the Midlands Region, with 22 sites allocated per lot to allow the Commissioner to ensure an even geographical spread. Should fewer than 22 sites be awarded to a Lot, up to 4 additional sites may be awarded under alternative Lot(s) at the Commissioners discretion. The ICB's included in this procurement are NHS Black Country ICB, NHS Leicester, Leicestershire, & Rutland ICB & NHS Birmingham and Solihull ICB.<br/><br/>The value of the service provision resulting from this Procurement Process will be an Item of Service (IoS) fee of £9.58 for the administration of each RSV and pertussis vaccine to each eligible patient.<br/><br/>The number of eligible patients, and therefore the likely activity level, could change as a result of factors beyond the Commissioner’s control such as an increase or decrease in population of the local area, closure or merger of other nearby NHS health organisations, or patient.<br/><br/>Services will commence in May 2025 and will continue until 31st March 2027, with an option for the Commissioner to extend for 24 months until 31 March 2029.<br/><br/>The award criteria is as stated below:<br/><br/>Integration, collaboration and service sustainability - 20.00%<br/>Improving access, reducing health inequalities and facilitating choice - 45.00%<br/>Quality and Innovation - 25.00%<br/>Social Value - 10.00%<br/>Value - Pass / Fail<br/><br/>Please note the deadline for responses to the ITT is 12:00PM (Mid-Day) on Friday 14th March 2025.
II.2.5) Meini prawf dyfarnu
Nid pris yw’r unig faen prawf dyfarnu a dim ond yn y dogfennau caffael y mae’r holl feini prawf wedi’u nodi
II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig
Dechrau:
01/05/2025
Diwedd:
31/03/2029
Gall y contract hwn gael ei adnewyddu: Na
II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd
II.2.10) Gwybodaeth am amrywiadau
Derbynnir amrywiadau:
Na
II.2.11) Gwybodaeth am opsiynau
Opsiynau:
Ydy
Disgrifiad o’r opsiynau:
Services will commence in May 2025 and will continue until 31st March 2027, with an option for the Commissioner to extend for 24 months until 31 March 2029.
II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd
Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd:
Na
Section III: Gwybodaeth gyfreithiol, economaidd, ariannol a thechnegol
III.1) Amodau ar gyfer cymryd rhan
III.1.2) Statws economaidd ac ariannol
Meini prawf dethol fel y’u nodir yn y dogfennau caffael
III.1.3) Gallu technegol a phroffesiynol
Meini prawf dethol fel y’u nodir yn y dogfennau caffael
III.2) Amodau sy’n gysylltiedig â’r contract
Section IV: Gweithdrefn
IV.1) Disgrifiad
IV.1.1) Y math o weithdrefn
Gweithdrefn agored
IV.1.8) Gwybodaeth am Gytundeb Caffael y Llywodraeth (GPA)
The procurement is covered by the Government Procurement Agreement:
Ydy
IV.2) Gwybodaeth weinyddol
IV.2.2) Terfyn amser i dendrau neu geisiadau i gymryd rhan ddod i law
Dyddiad:
14/03/2025
Amser lleol: 12:00
IV.2.4) Ym mha iaith/ieithoedd y gellir cyflwyno tendrau neu geisiadau i gymryd rhan
EN
IV.2.6) Yr isafswm cyfnod gofynnol i’r sawl sy’n tendro gynnal y tendr
Hyd mewn misoedd: 6 (o’r dyddiad a nodwyd i dendr ddod i law)
IV.2.7) Amodau ar gyfer agor tendrau
Dyddiad:
14/03/2025
Amser lleol: 13:00
Section VI: Gwybodaeth ategol
VI.1) Gwybodaeth am ailddigwydd
Caffaeliad cylchol yw hwn:
Na
VI.3) Gwybodaeth ychwanegol
This is a Provider Selection Regime (PSR) Contract Notice. The awarding of this contract is subject to the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015 do not apply to this award.<br/><br/>The Contracting Authority will be using an eTendering system for this procurement exercise.<br/><br/>Further information and the ITT documentation can be found via the 'Live Opportunities' list on the e-tendering system at the following link:<br/><br/>https://health-family-contract-search.secure.force.com/?searchtype=Projects<br/><br/>You can also register your interest via this page. You can search for the opportunity by entering the following contract reference: C342898 - COMP: Community Pharmacy RSV and Pertussis Vaccination Enhanced Service<br/><br/>Neither the publication of this notice nor the employment of any particular terminology nor any other indication shall be taken to mean that the Contracting Authority intends to hold itself bound by any of the Regulations.<br/><br/>The award criteria is as stated below:<br/><br/>Integration, collaboration and service sustainability - 20.00%<br/>Improving access, reducing health inequalities and facilitating choice - 45.00%<br/>Quality and Innovation - 25.00%<br/>Social Value - 10.00%<br/>Value - Pass / Fail<br/><br/>Please see published procurement documentation for further details. All relevant information on the stages of evaluation are stated within the ITT documentation suite.
VI.4) Gweithdrefnau adolygu
VI.4.1) Corff adolygu
NHS England
Wellington House, 133-135 Waterloo Rd
London
SE1 8UG
UK
Cyfeiriad(au) rhyngrwyd
URL: https://www.england.nhs.uk/
VI.4.2) Corff sy’n gyfrifol am weithdrefnau cyfryngu
NHS Arden and GEM CSU
St John's House, East Street
Leicester
LE1 6NB
UK
Cyfeiriad(au) rhyngrwyd
URL: https://www.ardengemcsu.nhs.uk/
VI.5) Dyddiad anfon yr hysbysiad hwn
03/03/2025